Pediatric Nephrology

, Volume 22, Issue 3, pp 403–408 | Cite as

High-sensitivity C-reactive protein (hs-CRP) level in children with nephrotic syndrome

  • Anna Wasilewska
  • Walentyna Zoch-Zwierz
  • Jolanta Tobolczyk
  • Edyta Tenderenda
Original Article


The aim of this study was to assess the serum concentration of high-sensitivity C-reactive protein (hs-CRP) in children with nephrotic syndrome (NS) treated with prednisone and cyclosporine A (CyA). Patients were divided into three groups: (I) 20 NS children (aged 4–14 years) in relapse and examined twice, (A) before treatment and (B) after proteinuria regression (a 3–4 week course of prednisone therapy); (II) 20 children with steroid-dependent or steroid-resistant NS, treated with CyA, also examined twice, (D) before treatment with CyA, (E) 6 months after therapy. A control group (C) consisted of 20 healthy children. Serum hs-CRP level was determined by a nephelometric method with a Behring Nephelometer 100 Analyzer, Dade Behring. The results showed that median hs-CRP concentration was the highest in children with relapsing steroid-sensitive NS before treatment (IA). After proteinuria regression (IB), the hs-CRP level had decreased and did not differ from that of healthy controls (C) (P > 0.05). In group II, before CyA administration (IID), the level of hs-CRP was normal, but it had increased after 6 months of treatment (IIE) up to a level six-times higher than that of the control group (P < 0.01). We concluded that, in children with steroid-sensitive nephrotic syndrome in relapse, the serum hs-CRP level is increased but returns to normal after 3–4 weeks of glucocorticoid treatment. In children chronically treated with CyA due to NS, serum hs-CRP level increases significantly during the therapy.


Children hs-CRP Nephrotic syndrome Cyclosporine 



We thank Dr. Tony Merry of Glycosciences Consultancy, Oxford and the University of Manchester, England, for his critical evaluation of the manuscript and for his help with the English text.


  1. 1.
    Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH (1993) The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44:638–642PubMedGoogle Scholar
  2. 2.
    Watts GF, Herrmann S, Dogra GK, Playford DA, Best JD, Thomas MA, Irish A (2001) Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 60:182–189PubMedCrossRefGoogle Scholar
  3. 3.
    Suranyi MG, Guasch A, Hall BM, Myers BD (1993) Elevated levels of tumor necrosis factor-alpha in the nephrotic syndrome in humans. Am J Kidney Dis 21:251–259PubMedGoogle Scholar
  4. 4.
    Stenvinkel P, Ottosson-Seeberger A, Alvestrand A (1995) Renal hemodynamics and sodium handling in moderate renal insufficiency: the role of insulin resistance and dyslipidemia. J Am Soc Nephrol 5:1751–1760PubMedGoogle Scholar
  5. 5.
    Zdrojewski T, Chwojnicki K, Bandosz P, Konarski R, Wyrzykowski B (2006) Distribution of C-reactive protein and its relation to arterial hypertension in a country representing a high-risk region for cardiovascular diseases. Blood Press 15:20–26PubMedCrossRefGoogle Scholar
  6. 6.
    Pfutzner A, Forst T (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8:28–36PubMedCrossRefGoogle Scholar
  7. 7.
    Du Clos TW, Mold C (2004) C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res 30:261–277PubMedCrossRefGoogle Scholar
  8. 8.
    Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, Fricke L, Steinhoff J (2003) The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 33:152–161PubMedCrossRefGoogle Scholar
  9. 9.
    Blake GJ, Ridker PM (2002) Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 252:283–294PubMedCrossRefGoogle Scholar
  10. 10.
    Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, Rifai N (2001) Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 47:418–425PubMedGoogle Scholar
  11. 11.
    Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N (2000) Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 46:461–468PubMedGoogle Scholar
  12. 12.
    Lambert M, Delvin EE, Paradis G, O’Loughlin J, Hanley JA, Levy E (2004) C-reactive protein and features of the metabolic syndrome in a population-based sample of children and adolescents. Clin Chem 50:1762–1768PubMedCrossRefGoogle Scholar
  13. 13.
    Shah SJ, Marcus GM, Gerber IL, McKeown BH, Vessey JC, Jordan MV, Huddleston M, Foster E, Chatterjee K, Michaels AD (2006) High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. J Card Fail 2:61–65CrossRefGoogle Scholar
  14. 14.
    Stenvinkel P, Lindholm B (2005) C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 23:72–78PubMedCrossRefGoogle Scholar
  15. 15.
    Rifai N, Ridker PM (2001) High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47:403–411PubMedGoogle Scholar
  16. 16.
    Ridker PM (2004) High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 148:S19–S26PubMedCrossRefGoogle Scholar
  17. 17.
    Ueland T, Vissers MN, Wiegman A, Rodenburg J, Hutten B, Gullestad L, Ose L, Rifai N, Ridker PM, Kastelein JJ, Aukrust P, Semb AG (2006) Increased inflammatory markers in children with familial hypercholesterolaemia. Eur J Clin Invest 36:147–152PubMedCrossRefGoogle Scholar
  18. 18.
    Eskola J, Holmberg C, Koskimies O (1986) C-reactive protein—an indicator of generalized bacterial infection in children with nephrotic syndrome. Acta Paediatr Scand 75:846–848PubMedGoogle Scholar
  19. 19.
    Araujo F, Pereira AC, Latorre Mdo R, Krieger JE, Mansur AJ (2004) High-sensitivity C-reactive protein concentration in a healthy Brazilian population. Int J Cardiol 97:433–438PubMedCrossRefGoogle Scholar
  20. 20.
    Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, Park JR, Kim SW (2003) High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 16:429–433PubMedCrossRefGoogle Scholar
  21. 21.
    Coulon J, Willems D, Dorchy H (2005) Increase in C-reactive protein plasma levels during diabetes in infants and young adults. Presse Med 34:89–93PubMedGoogle Scholar
  22. 22.
    Li C, Yang CW, Kim WY, Jung JY, Cha JH, Kim YS, Kim J, Bennett WM, Bang BK (2003) Reversibility of chronic cyclosporine nephropathy in rats after withdrawal of cyclosporine. Am J Physiol Renal Physiol 284:F389–F398PubMedGoogle Scholar
  23. 23.
    Nakahara C, Kanemoto K, Saito N, Oyake Y, Kamoda T, Nagata M, Matsui A (2001) C-reactive protein frequently localizes in the kidney in glomerular diseases. Clin Nephrol 55:365–370PubMedGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Anna Wasilewska
    • 1
  • Walentyna Zoch-Zwierz
    • 1
  • Jolanta Tobolczyk
    • 1
    • 2
  • Edyta Tenderenda
    • 1
  1. 1.1st Department of PediatricsMedical University of BiałystokBiałystokPoland
  2. 2.Department of Pediatric AllergologyMedical University of BiałystokBiałystokPoland

Personalised recommendations